KL
Therapeutic Areas
IMUNON Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMNN-001 (TheraPlas™-IL-12) | Advanced Ovarian Cancer (Epithelial Ovarian Cancer) | Phase 2 |
| PlaCCine Platform | Infectious Diseases (SARS-CoV-2 validation) | Pre-clinical |
Leadership Team at IMUNON
SR
Stacy R. Lindborg
President, Chief Executive Officer & Board Director
DV
Douglas V. Faller
Chief Medical Officer
JW
Jeffrey W. Church
Interim Chief Financial Officer
KA
Khursheed Anwer
Executive Vice President and Chief Science Officer
SH
Sebastien Hazard
Executive Vice President & Chief Medical Officer
SE
Susan Eylward
General Counsel & Corporate Secretary
MH
Michael H. Tardugno
Board of Directors
FJ
Frederick J. Fritz
Board of Directors
DB
Donald Braun
Board of Directors
CP
Christine Pellizzari
Board of Directors